X
Xingrong Fan
Researcher at Peking Union Medical College
Publications - 9
Citations - 130
Xingrong Fan is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 79 citations.
Papers
More filters
Journal ArticleDOI
First-in-human study of 177 Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Jie Zang,Xingrong Fan,Hao Wang,Qingxing Liu,Jingnan Wang,Hui Li,Fang Li,Orit Jacobson,Gang Niu,Zhaohui Zhu,Zhaohui Zhu,Xiaoyuan Chen +11 more
TL;DR: This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in treating tumors with high 68Ga-PSma-617 uptakes.
Journal ArticleDOI
PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients.
Jingjing Zhang,Jingjing Zhang,Gang Niu,Xingrong Fan,Lixin Lang,Guozhu Hou,Li-Bo Chen,Huanwen Wu,Zhaohui Zhu,Fang Li,Xiaoyuan Chen +10 more
TL;DR: 68Ga-RM26 PET/CT would have remarkable value in detecting both primary prostate cancer and metastasis and is expected to be better than GRPR agonist as an imaging marker to evaluate GRPR expression in prostate cancer.
Journal ArticleDOI
A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Guochang Wang,Jie Zhang,Yuanyuan Jiang,Qingxing Liu,Huimin Sui,Rong Fu Wang,Xingrong Fan,Jingjing Zhang,Zhaohui Zhu +8 more
TL;DR: In this paper , the safety and therapeutic efficacy of radioligand therapy (RLT) of 177Lu-EB-prostate-specific membrane antigen (PSMA) in patients with metastatic castration-resistant prostate cancer were investigated.
Journal ArticleDOI
Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study
Lin-Geer Wu,Yan-zhen Xu,Xiang Wang,Xinqi Cheng,Yuelun Zhang,Yingyi Wang,Xingrong Fan,Haitao Zhao,He Liu,Xiaofeng Chai,Li Zhang,Mengzhao Wang,Naishi Li,Hui Pan,Xiaolan Lian +14 more
TL;DR: Wang et al. as mentioned in this paper retrospectively reviewed patients with carcinoma who received immune checkpoint inhibitor (ICI) therapy and underwent evaluation of thyroid function during hospitalization at Peking Union Medical College Hospital between January 1, 2017 and December 31, 2020.
Journal ArticleDOI
Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle‐invasive bladder cancer: A multi‐center, single‐arm, phase 2 study
Sujun Han,Zhigang Ji,Junhui Jiang,Xingrong Fan,Qi Ma,Likuan Hu,Wen Zhang,Hao Ping,Jiansong Wang,Wanhai Xu,Benkang Shi,Wei Wang,Haifeng Wang,Honglei Wang,Shouzhen Chen,Hailong Hu,Jianming Guo,Shuai Jiang,Quan Zhou,N. Xing +19 more
TL;DR: In this article , the authors investigated the efficacy and safety of neoadjuvant camrelizumab in combination with gemcitabine plus cisplatin (GC) followed by RC for MIBC patients.